Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;103(12):5019-5033.
doi: 10.1007/s00277-024-06050-x. Epub 2024 Oct 29.

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment

Shan Zheng  1   2   3 , Yuxin Tong  1   2   3 , Linlin Yang  2   3 , Jiayi Chen  1   2   3 , Yamin Tan  4   5
Affiliations
Review

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment

Shan Zheng et al. Ann Hematol. 2024 Dec.

Abstract

Acute myeloid leukemia (AML) is the most prevalent hematologic malignancy in adults. In 2022, the European LeukemiaNet (ELN) has updated its prognostic system that incorporates cytogenetics and molecular genetics based on data from patients undergoing intensive chemotherapy (IC). Recently, a risk stratification framework has been established for hypomethylating agents (HMA)-based low-intensity treatment (LIT) to fill the gaps in stratification for this treatment modality, but this needs further refinement. Venetoclax (VEN), a BH3 mimetic, targets BCL-2 to modulate apoptosis and metabolism in AML cells. Its combination with HMA or low-dose cytarabine (LDAC) has been shown to enhance the response rates and prolong the survival outcomes of older or unfit patients with AML. In this review, we delved into the prognostic significance of FLT3-ITD and IDH mutations when used in combination with VEN and HMA, as well as in conjunction with their specific inhibitors. We also explored the role of VEN in NPM1-mutated AML and its efficacy in splicing factor mutations AML. Additionally, we examined the response rates and survival outcomes of CBF-AML when treated with a VEN-based regimen. Moving forward, it is imperative that risk stratification for LIT becomes more nuanced to better align with the requirements of personalized diagnosis and treatment strategies.

Keywords: Acute myeloid leukemia; Cytogenetics; Molecular genetics; Prognosis; Venetoclax.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interest: The authors declare no competing interests.

References

    1. Döhner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136–1152. https://doi.org/10.1056/NEJMra1406184 - DOI - PubMed
    1. Sasaki K, Ravandi F, Kadia TM et al (2021) De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and end results (SEER) database, 1980 to 2017. Cancer 127:2049–2061. https://doi.org/10.1002/cncr.33458 - DOI - PubMed
    1. Döhner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345–1377. https://doi.org/10.1182/blood.2022016867 - DOI - PubMed
    1. Gupta N, Miller A, Gandhi S et al (2015) Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥ 60 years old. Am J Hematol 90:639–646. https://doi.org/10.1002/ajh.24016 - DOI - PubMed - PMC
    1. Rausch C, Rothenberg-Thurley M, Dufour A et al (2023) Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia 37:1234–1244. https://doi.org/10.1038/s41375-023-01884-2 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources